Stockscreener 앱 받기
0.68
1.43%
0.0096
시간 외 거래:
.67
-0.01
-1.47%
전일 마감가:
$0.6704
열려 있는:
$0.67
하루 거래량:
1.67M
Relative Volume:
0.06
시가총액:
$10.12M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-0.00821
EPS:
-82.86
순현금흐름:
$-9.78M
1주 성능:
-1.59%
1개월 성능:
+282.45%
6개월 성능:
+8.97%
1년 성능:
-24.86%
1일 변동 폭
$0.64
$0.71
1주일 범위
$0.615
$0.81
52주 변동 폭
$0.1412
$2.06
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ENSC | 0.68 | 10.12M | 0 | -11.28M | -9.78M | -82.86 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Anson Funds Management LP Acquires New Stake in Ensysce Bioscien - GuruFocus.com
Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate - Simply Wall St
Comparing Ensysce Biosciences (NASDAQ:ENSC) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Defense World
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 5,514.5% in October - Defense World
Ensysce Biosciences Reports Improved Financial Results - TipRanks
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ensysce Biosciences Reports Third Quarter 2024 Financial Results - AccessWire
Ensysce Biosciences Secures $14M NIH Grant, Swings to Q3 Profit Amid Clinical Progress | ENSC Stock News - StockTitan
Ensysce Biosciences granted Nasdaq listing extension By Investing.com - Investing.com Canada
Ensysce Biosciences granted Nasdaq listing extension - Investing.com
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - AccessWire
Ensysce Biosciences Secures Critical Nasdaq Extension Through 2024 Amid Listing Challenges | ENSC Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Ensysce Biosci - GuruFocus.com
Ensysce Biosciences (NASDAQ:ENSC) Trading Down 9.8% – What’s Next? - Defense World
Ensysce Biosciences Presenting at Upcoming Meetings - GuruFocus.com
Perceptive Advisors LLC's Strategic Acquisition of Ensysce Biosc - GuruFocus.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss - Benzinga
Regeneron Pharmaceuticals (REGN) Stock Drops Amid Market Volatility - GuruFocus.com
Advaxis (ADXS) Sees 112.96% Surge Amid Market Volatility - GuruFocus.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ensysce Biosciences adjusts quorum requirement for stockholder meetings - Investing.com India
Ensysce Biosciences adjusts quorum requirement for stockholder meetings By Investing.com - Investing.com South Africa
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Inc (ENSC) presents a great opportunity, but the stock is slightly undervalued - US Post News
ENSC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Closing Figures: Ensysce Biosciences Inc (ENSC)’s Negative Finish at 0.17, Down -4.39 - The Dwinnex
Anchoring Your Portfolio: Is ENSC Stock a Safe Harbor? - The InvestChronicle
Ensysce Biosciences Inc (ENSC) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Market Momentum: Ensysce Biosciences Inc (ENSC) Registers a -14.87 Decrease, Closing at 0.19 - The Dwinnex
ENSC stock touches 52-week low at $0.19 amid market challenges By Investing.com - Investing.com South Africa
ENSC stock touches 52-week low at $0.19 amid market challenges - Investing.com
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit - StockTitan
Ensysce meets Nasdaq requirements, advances pain treatment - Investing.com
Ensysce meets Nasdaq requirements, advances pain treatment By Investing.com - Investing.com Canada
Ensysce Biosciences responds to recent shareholder inquiries - TipRanks
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries - AccessWire
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries | ENSC Stock News - StockTitan
ENSC stock touches 52-week low at $0.23 amid market challenges - Investing.com Canada
ENSC Stock Update: Ensysce Biosciences Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Ratio Analysis: Unpacking Ensysce Biosciences Inc (ENSC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ensysce Biosciences faces Nasdaq delisting over noncompliance By Investing.com - Investing.com Australia
Ensysce Biosciences faces Nasdaq delisting over noncompliance - Investing.com
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Ensysce Biosciences Receives Notice from Nasdaq - AccessWire
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update - Defense World
ENSC stock touches 52-week low at $0.31 amid market challenges - Investing.com Canada
Ensysce Biosciences submits Phase 3 study protocol for pain treatment - Investing.com
Ensysce Biosciences submits Phase 3 study protocol for pain treatment By Investing.com - Investing.com Australia
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):